{
  "drugs": [
    {
      "drug": "sotorasib (AMG-510)",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Covalently binds the GDP-bound inactive state of KRAS G12C (switch II pocket), locking it inactive and blocking downstream RAF/MEK/ERK signaling.",
      "fda_status": "Approved for NSCLC and colorectal cancer",
      "category": "repurposing_candidate"
    },
    {
      "drug": "adagrasib",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Covalently binds the GDP-bound inactive state of KRAS G12C (switch II pocket), locking it inactive and blocking downstream RAF/MEK/ERK signaling.",
      "fda_status": "Approved for NSCLC and colorectal cancer",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Daraxonrasib (RMC-6236)",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Pan-RAS(ON) inhibitor targeting active GTP-bound states of KRAS G12C, G12D, and G12V.",
      "fda_status": "Phase 1/3 trials",
      "category": "repurposing_candidate"
    },
    {
      "drug": "RMC-7977",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Pan-KRAS inhibitor with significant antitumor activity.",
      "fda_status": "Preclinical/early-stage",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Trametinib",
      "proteins": [
        "KRAS",
        "ERK2"
      ],
      "mechanism": "MEK1/2 inhibitor blocking MAPK pathway downstream of KRAS; upstream MEK1/2 inhibitor affecting ERK2 activation.",
      "fda_status": "FDA-approved for other cancers (e.g., colorectal)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "RMC-4630",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "SHP2 inhibitor to block RAS-MAPK signaling.",
      "fda_status": "Phase 1/1b trials",
      "category": "repurposing_candidate"
    },
    {
      "drug": "LY3214996",
      "proteins": [
        "ERK2"
      ],
      "mechanism": "ERK inhibitor.",
      "fda_status": "Phase 1/1b trials",
      "category": "repurposing_candidate"
    },
    {
      "drug": "IMM-6-415",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Immunotherapy targeting KRAS.",
      "fda_status": "Phase 1/2",
      "category": "repurposing_candidate"
    },
    {
      "drug": "ARV-806",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Targets KRAS G12D.",
      "fda_status": "Early-stage",
      "category": "repurposing_candidate"
    },
    {
      "drug": "ELI-002 7P",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Vaccine targeting KRAS.",
      "fda_status": "Phase 1/2",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Disulfiram",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Covalently binds KRAS via copper-mediated mechanisms, inhibiting KRAS activity.",
      "fda_status": "Approved for alcohol use disorder",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Metformin",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Indirectly suppresses KRAS signaling via AMPK activation.",
      "fda_status": "Approved for type 2 diabetes",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Aspirin",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Binds to switch-II pocket of KRAS, inhibiting G12D/C mutants.",
      "fda_status": "Approved for analgesic, anti-inflammatory use",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Simvastatin",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Inhibits KRAS prenylation via farnesyl pyrophosphate depletion.",
      "fda_status": "Approved for hypercholesterolemia",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Propranolol",
      "proteins": [
        "ERK2"
      ],
      "mechanism": "Off-target ERK inhibition.",
      "fda_status": "Approved for hypertension",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Itraconazole",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Disrupts KRAS-GLI1 axis.",
      "fda_status": "Approved for fungal infections",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Thalidomide",
      "proteins": [
        "ERK2"
      ],
      "mechanism": "Binds to ERK kinase domain, inhibiting phosphorylation.",
      "fda_status": "Approved for multiple myeloma",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Cimetidine",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Inhibits histamine-RAS-ERK axis.",
      "fda_status": "Approved for peptic ulcers",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Verapamil",
      "proteins": [
        "ERK2"
      ],
      "mechanism": "Off-target MAPK/ERK2 inhibition.",
      "fda_status": "Approved for hypertension",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Doxycycline",
      "proteins": [
        "KRAS",
        "ERK2"
      ],
      "mechanism": "Direct docking hits and indirect block of RAS-ERK via MMP inhibition.",
      "fda_status": "Approved for bacterial infections",
      "category": "repurposing_candidate"
    }
  ],
  "cancer_type": "pancreatic ductal adenocarcinoma",
  "protein_targets": [
    "KRAS",
    "ERK2"
  ]
}